First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis

First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis

<b>Background:</b> HER2 mutations are rare driver events in advanced NSCLC, with limited relief from current targeted therapies. This study aimed to characterize the molecular features of HER2-mutant NSCLC and to evaluate the clinical efficacy of pyrotinib-based combination therapy as a...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Xiang, Meiling Zhang, Qian Wang, Jingwen Liu, Lulin Zeng, Ao Sun, Kaihua Lu
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Current Oncology
Subjects:
human epidermal growth factor receptor 2
non-small-cell lung cancer
pyrotinib
combination therapy
safety
Online Access:https://www.mdpi.com/1718-7729/32/3/148
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/3/148

Similar Items